Info@ThinkPinkRocks.com

Secondary non-Hodgkin’s lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin’s lymphoma than the general population, study findings indicate.

Follow this link:
Secondary non-Hodgkin’s lymphoma a concern for CML patients using TKIs

Share

Leave a Reply

Solve : *
17 + 28 =